Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
Miyao K, Kuwatsuka Y, Murata M, Nagafuji K, Teshima T, Takeuchi Y, Shiratori S, Najima Y, Uchida N, Tanaka M, Sawa M, Ota S, Fukuda T, Ozawa Y, Kako S, Kawakita T, Ara T, Tanaka J, Kanda Y, Atsuta Y, Kanda J, Terakura S; GVHD Working Group and Donor/Source Working Group of the Japanese Society for Transplantation and Cellular Therapy.
Miyao K, et al.
Transplant Cell Ther. 2022 Mar;28(3):153.e1-153.e11. doi: 10.1016/j.jtct.2021.12.009. Epub 2021 Dec 22.
Transplant Cell Ther. 2022.
PMID: 34954151
Free article.
The incidences of acute GVHD, chronic GVHD, and NRM and chronic GVHD-free relapse-free survival rates were comparable between the PBSCT-ATG(+) and BMT groups. ...Prophylactic ATG was found to be a promising strategy against GVHD....
The incidences of acute GVHD, chronic GVHD, and NRM and chronic GVHD-free relapse-free survival rates were comparable b …